MX2018000657A - Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. - Google Patents

Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.

Info

Publication number
MX2018000657A
MX2018000657A MX2018000657A MX2018000657A MX2018000657A MX 2018000657 A MX2018000657 A MX 2018000657A MX 2018000657 A MX2018000657 A MX 2018000657A MX 2018000657 A MX2018000657 A MX 2018000657A MX 2018000657 A MX2018000657 A MX 2018000657A
Authority
MX
Mexico
Prior art keywords
hydroxytryptamine
renewal
differentiation
promoter
receptor
Prior art date
Application number
MX2018000657A
Other languages
English (en)
Inventor
Bruno Chretien Fabrice
Gaillard Raphael
Rocheteau Pierre
Mir Olivier
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2018000657A publication Critical patent/MX2018000657A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere al campo de la regeneración de músculos y más en particular a la reposición del conjunto de células madre musculares in vivo; se refiere más específicamente a un agente estimulador del receptor 5-hidroxitriptamina B1 y a una composición que comprende dicho agente, para usarse como i) un promotor de la autorrenovación y/o diferenciación de células satélite y/o ii) un agente que previene e/o inhibe el agotamiento del grupo de células satélite; la invención además abarca métodos terapéuticos y de detección.
MX2018000657A 2015-07-17 2016-07-15 Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. MX2018000657A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193714P 2015-07-17 2015-07-17
EP16305444 2016-04-15
PCT/EP2016/066948 WO2017013031A1 (en) 2015-07-17 2016-07-15 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation

Publications (1)

Publication Number Publication Date
MX2018000657A true MX2018000657A (es) 2018-09-06

Family

ID=55808532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000657A MX2018000657A (es) 2015-07-17 2016-07-15 Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.

Country Status (9)

Country Link
US (2) US10493046B2 (es)
EP (2) EP3799873A1 (es)
JP (1) JP7000321B2 (es)
CN (1) CN108348486A (es)
AU (1) AU2016296205B2 (es)
BR (1) BR112018000841A8 (es)
CA (1) CA2992161A1 (es)
MX (1) MX2018000657A (es)
WO (1) WO2017013031A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7000321B2 (ja) 2015-07-17 2022-02-10 アンスティテュ・パストゥール 衛星細胞の自己再生および／または分化の促進剤としての使用のための５－ヒドロキシトリプタミン１ｂ受容体刺激剤
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
US20210284615A1 (en) * 2016-07-22 2021-09-16 Qingeng Li Vortioxetine analogue and use and preparation thereof
JP2021008409A (ja) * 2019-06-28 2021-01-28 佐藤製薬株式会社 筋再生促進剤
CN110988351B (zh) * 2019-09-05 2023-10-20 首都医科大学附属北京安定医院 血管细胞黏附分子在制备抑郁症诊断治疗相关产品的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
ATE507214T1 (de) * 2006-06-22 2011-05-15 Univ Ramot Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2120944A1 (en) 2006-12-22 2009-11-25 Medestea Internazionale S.p.A. A novel use of antidepressant compounds and related compositions
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
GB0907350D0 (en) * 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
MY162132A (en) 2010-06-23 2017-05-31 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US9248185B2 (en) * 2011-06-16 2016-02-02 President And Fellows Of Harvard College Methods of increasing satellite cell proliferation
GB201120259D0 (en) 2011-11-24 2012-01-04 Univ Gent Allogeneic immune response control
US20140121256A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
CN104853755B (zh) * 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
US20160101093A1 (en) 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
JP7000321B2 (ja) 2015-07-17 2022-02-10 アンスティテュ・パストゥール 衛星細胞の自己再生および／または分化の促進剤としての使用のための５－ヒドロキシトリプタミン１ｂ受容体刺激剤
EP3362058B1 (en) 2015-10-14 2021-09-01 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
JP2019524723A (ja) 2016-07-15 2019-09-05 アンスティテュ・パストゥール 皮膚および／または毛の修復のための５−ヒドロキシトリプタミン１ｂ受容体刺激剤

Also Published As

Publication number Publication date
EP3799873A1 (en) 2021-04-07
CN108348486A (zh) 2018-07-31
US20200060999A1 (en) 2020-02-27
JP2018521140A (ja) 2018-08-02
EP3324952B1 (en) 2020-12-16
WO2017013031A1 (en) 2017-01-26
AU2016296205A1 (en) 2018-02-01
EP3324952A1 (en) 2018-05-30
US11344515B2 (en) 2022-05-31
US10493046B2 (en) 2019-12-03
AU2016296205B2 (en) 2021-11-11
BR112018000841A8 (pt) 2022-11-22
US20180200207A1 (en) 2018-07-19
BR112018000841A2 (pt) 2018-09-11
CA2992161A1 (en) 2017-01-26
JP7000321B2 (ja) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2018000657A (es) Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
PH12017502107A1 (en) Triazole agonists of the apj receptor
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2018006195A (es) Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX2012008440A (es) Tratamiento de enfermedades cardiacas.
MX2017005457A (es) Metodos y compuestos agonistas de gip.
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2021010545A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
WO2016061509A8 (en) Compositions and methods of treating muscular dystrophy
UA118201C2 (uk) НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
MX360774B (es) Antagonistas de progesterona.
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MY188227A (en) Settable compositions comprising wollastonite and pumice and methods of use
MX2016016756A (es) Terapia con células madre en patologías endometriales.
MX2019005831A (es) Aptameros para usarse en la inhibicion y/o supresion de la activacion de tlr9.
MX2016012937A (es) Compuestos de azol amido-sutituidos como inhibidores de tnks1 y/o tnks2.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
IL287981A (en) Preparations and methods for the treatment of t-cell exhaustion
EP3669884A4 (en) COMPOSITION FOR THE TREATMENT OF THYROID-ASSOCIATED OPHTHALMOPATHY INCLUDING A MESENCHYMATIC STEM CELL